FDA seeks to pull OTC nasal decongestant ingredient due to lack of efficacy
After 17 years of back and forth with citizen petitions and two advisory committees, the FDA on Thursday proposed to pull commonly-used nasal decongestant active ingredients in common over-the-counter...
View ArticleVaccine makers face headwinds from RFK, soft demand and China
Coming out of Covid, the vaccine market appeared to experience a renaissance as the innovations of the pandemic unleashed new products and a new impetus to prevent infections. But just a few years...
View ArticleStephen Squinto's JPM life sciences team is raising a new fund for...
CHICAGO — Stephen Squinto, recruited by JP Morgan a few years ago to head up its Life Sciences Private Capital team, is raising a second fund geared toward more growth-stage opportunities. ...
View ArticleSenior AstraZeneca exec detained in China amid wider investigation
The head of AstraZeneca’s operations in China has been detained by authorities there, the company confirmed. Prior to his detainment, Leon Wang, executive vice president of international and president...
View ArticlePfizer to invest $1B in China over next five years — reports
Pfizer is doubling down on its commitment to China as the company continues to face activist pressure around its plans for a new phase of growth. Pfizer China President Jean-Christophe Pointeau said ...
View ArticleNkarta drops another cancer program as it leans into autoimmune disease
Nkarta is punting development of a natural killer cell therapy in cancer to focus instead on the same candidate's prospects in autoimmune disease. The biotech will stop investigating NKX019 in...
View ArticleLegend names a president of Carvykti; Novo Nordisk's top North America exec...
Alan Bash is joining Legend Biotech as its president of Carvykti, an unconventional, newly-created role to oversee the commercial future of the biotech's sole marketed cell therapy, among other...
View ArticleBenevolentAI co-founder returns with plan to save drug developer
Can Ken Mulvany save BenevolentAI? About a decade ago, Mulvany helped found the company as part of the first generation of AI-focused biotech startups. It soared to a $2 billion valuation, pitching a...
View ArticleDaiichi, Alteogen to work on subcutaneous Enhertu; Roche ends Nykode deal
Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the...
View ArticleEisai slashes Leqembi sales forecast by almost $100M
Eisai has slashed Leqembi's sales forecast by 25% this year, lowering the ceiling for one of the industry's most closely-watched drugs. The company now expects that the Alzheimer's treatment will bring...
View ArticleAmgen and AstraZeneca share positive results in chronic rhinosinusitis
Amgen and AstraZeneca said on Friday that their asthma drug Tezspire reduced nasal congestion and the size of nasal polyps in patients with a different but sometimes related inflammatory condition....
View ArticleFDA action puts Chinese API manufacturer on import block list
The FDA this week posted an untitled letter sent Oct. 17 to China-based active pharmaceutical ingredient (API) manufacturer Shandong Boyuan Pharmaceutical Co., whose exports to the US have been blocked...
View ArticleHow Trump, RFK Jr. could influence biopharma; Viking presents weight loss...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleUpdated: FDA approves Autolus’ CAR-T cell therapy for aggressive blood cancer
US regulators gave the green light to Autolus Therapeutics’ cell therapy for adult B cell precursor acute lymphoblastic leukemia, or B-ALL, that has returned or is not responding to prior treatment....
View ArticleAurion, Alcon enter legal battle over IPO plan
The eye giant Alcon has launched an unlikely legal battle, suing a cell therapy startup that it invested in and claiming its shareholder rights are being violated as Aurion Biotech prepares to go...
View ArticleALK-Abelló licenses ARS’ anaphylaxis nasal spray in certain markets for $145M
A Danish company is spending $145 million upfront for certain rights to the first-ever needle-free adrenaline nasal spray for severe allergic reactions, unlocking sales potential of more than $400...
View ArticleCigna says it will not pursue a merger with Humana
Cigna said it will not pursue a merger with rival Humana after reports last month of renewed talks about a potential deal. Talks of a deal
View Article